CCL14 biomarker results ≤ 1.30 ng/mL can be informative for certain aspects of AKI management and care processes of care, including drug dosing, exposure to nephrotoxins and family discussions on patient prognosis. The gene discussed is CCL14; the disease is acute kidney injury.